Conceptos básicos de PK, PD y PK/PD. Clasificación de los antibióticos de acuerdo a sus características PK/PD
7. BIBLIOGRAFÍA
Lectura de interés. Revisión
Lectura de interés. Metaanálisis
Lectura de interés. Ensayos clínicos
1 Ulldemolins M, Nuvials X, Palomar M, Masclans JR, Rello J. Appropriateness is critical; Crit Care Clin. 2011; 27 (1): 35-51.
2 Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases; Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions; Lancet Infect Dis. 2014; 14 (6): 498-509.
3 Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med. 2013;39 (12): 2070–2082.
4 Roberts JA, Lipman J; Pharmacokinetic issues for antibiotics in the critically ill patient; Crit Care Med. 2009; 37 (3): 840-851.
5 Ulldemolins M, Rello J; The relevance of drug volume of distribution in antibiotic dosing; Curr Pharm Biotechnol. 2011; 12 (12): 1996-2001.
6 Asín-Prieto E, Rodríguez-Gascón A, Isla A; Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents; J Infect Chemother. 2015; 21 (5): 319-29.
7 Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol. 2011;12(12):2070–2079.
8 McKinnon PS, Davis SL; Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases; Eur J Clin Microbiol Infect Dis. 2004; 23 (4): 271-288.
9 Jean-Louis Vincent, Matteo Bassetti, Bruno François, George Karam, Jean Chastre, Antoni Torres, et al. Advances in antibiotic therapy in the critically ill. Critical Care 2016; 20:133-146.
10 Heffernan AJ, Sime FB, Taccone FS, Roberts JA. How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients. Curr Opin Infect Dis. 2018 Oct 6. doi: 10.1097/QCO.0000000000000494. [Epub ahead of print]
11 Heffernan AJ, Sime FB, Lipman J, Roberts JA. Individualising Therapy to Minimize Bacterial Multidrug Resistance. Drugs. 2018;78(6):621-641.
12 Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17:479-501.
13 Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance.Am J Med. 2006; 119: S37-S44.
14 Wong G, Sime FB, Lipman J, Roberts JA. How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?. BMC Infect Dis. 2014; 14: 288 - 299.
15 Anouk E. Muller, Benedikt Huttner, Angela Huttner. Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections? Drugs 2018; 78: 439 – 451.
16 Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007; 30 (1): 11 - 18.
17 Roberts JA, Lipman J, Blot S and Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Current Opinion in Critical Care 2008, 14:390–396.
18 Lodise TP, Lomaestro B, and Drusano GL. Piperacillin-Tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357-363.
19 Abdul-Aziz MH1, Dulhunty JM, Bellomo R, Lipman J, Roberts JA. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care. 2012 Aug 16;2(1):37.
20 Jason A. Roberts, Jennifer Paratz, Elizabeth Paratz, Wolfgang A. Krueger, Jeffrey Lipman. Review. Continuous infusion of -lactam antibiotics in severe infections: a review of its role. International Journal of Antimicrobial Agents 2007; 30: 11–18.
21 Jason A. Roberts, Mohd-Hafiz Abdul-Aziz, Joshua S. Davis, Joel M. Dulhunty, Menino O. Cotta, John Myburgh. Continuous versus Intermittent b-Lactam Infusion in Severe Sepsis A Meta-analysis of Individual Patient Data from Randomized Trials. Am J Respir Crit Care Med 2016; 194 (6): 681–691.
22 Dong H1, Wang X, Dong Y, Lei J, Li H, You H, Wang M, Xing J, Sun J, Zhu H. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents. 2011;38(4):296-300.
23 De Pascale G, Fortuna S, Tumbarello M, Cutuli SL, Vallecoccia M, Spanu T, et al. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Med. 2015;41(1):103-110.
24 Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008;30(6):674-681.
25 Rea RS, Capitano B.Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med. 2007;28(6):596-603.
26 Daniel L. Brown, PharmD, Christina D. Lalla, PharmD Candidate, and Andrew J. Masselink, PharmD Candidate. AUC Versus Peak–Trough Dosing of Vancomycin: Applying New Pharmacokinetic Paradigms to an Old Drug. Ther Drug Monit 2013;35:443–449.
27 Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, Viale P. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2009;53(5):1863-1867.
28 Zayyad H, Eliakim-Raz N, Leibovici L, Paul M. Revival of old antibiotics: needs, the state of evidence and expectations. Int J Antimicrob Agents. 2017;49(5):536-541.